



ELK OrthoBiologics

Andrew M. Bray, PhD, Managing Director and CEO, Elk OrthoBiologics Limited

Dr Bray is the CEO and Managing Director of Elk OrthoBiologics Limited ('Elk'), an Australian company focused on the Phase 2 clinical development of a novel gene therapy for addressing orthopaedic conditions where there are few treatment options.

With a background in science innovation and business development, he has been actively involved in the biotechnology industry in Australia, USA and Europe since 1988. Following a period at CSL Limited in 1988, a large part of his career was spent at Chiron Corporation (acquired by Novartis), and Chiron Mimotopes, where as Chief Chemist he played a key role in establishing and leading a profitable Australian drug discovery and peptide business with an international reputation. Dr Bray is an inventor on 8 patent families and author on over 70 scientific papers and invited chapters. Dr Bray was actively involved in establishing drug discovery collaborations and technology transfers with pharmaceutical companies in USA, Europe and Japan, including Novartis, GSK, Japan Tobacco and Fujisawa (now Astellas), and universities including UC Berkeley and Tokyo Institute of Technology. In 2010 Dr Bray was appointed as the CEO of Elk OrthoBiologics.

Dr Bray completed a PhD in organic chemistry on DNA binding agents at the University of Melbourne in 1988 and undertook executive education at Monash Mt Eliza Business School in 1998.